Century Therapeutics (IPSC) to Release Earnings on Thursday

Century Therapeutics (NASDAQ:IPSC - Get Free Report) will likely be releasing its earnings data before the market opens on Thursday, March 13th. Analysts expect Century Therapeutics to post earnings of ($0.45) per share for the quarter.

Century Therapeutics Stock Up 0.1 %

NASDAQ:IPSC traded up $0.00 during midday trading on Friday, hitting $0.66. The company had a trading volume of 274,537 shares, compared to its average volume of 493,539. Century Therapeutics has a 52-week low of $0.57 and a 52-week high of $5.51. The stock's fifty day moving average price is $0.84 and its 200-day moving average price is $1.24. The company has a market capitalization of $55.73 million, a PE ratio of -0.35 and a beta of 1.75.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on IPSC. Guggenheim reiterated a "buy" rating on shares of Century Therapeutics in a research report on Wednesday, January 22nd. HC Wainwright restated a "buy" rating and set a $5.00 price target on shares of Century Therapeutics in a research report on Wednesday, January 22nd. Finally, Piper Sandler cut their price target on shares of Century Therapeutics from $12.00 to $4.00 and set an "overweight" rating for the company in a research report on Monday, December 30th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, Century Therapeutics has a consensus rating of "Buy" and an average target price of $10.00.

Remove Ads

Institutional Trading of Century Therapeutics

A hedge fund recently raised its stake in Century Therapeutics stock. Bank of America Corp DE grew its position in shares of Century Therapeutics, Inc. (NASDAQ:IPSC - Free Report) by 109.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 66,043 shares of the company's stock after acquiring an additional 34,466 shares during the period. Bank of America Corp DE owned about 0.08% of Century Therapeutics worth $67,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 50.20% of the company's stock.

About Century Therapeutics

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.